C-Rad
Market Cap
kr1.0b
Last Updated
2019/10/21 21:01 UTC
Data Sources
Company Financials
Executive Summary
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide.
Snowflake
Fundamentals
Flawless balance sheet with acceptable track record.
Similar Companies
Share Price & News
How has C-Rad's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
1.5%
CRAD B
5.5%
SE Medical Equipment
2.1%
SE Market
1 Year Return
24.8%
CRAD B
34.0%
SE Medical Equipment
12.1%
SE Market
Return vs Industry: CRAD B underperformed the Swedish Medical Equipment industry which returned 34% over the past year.
Return vs Market: CRAD B exceeded the Swedish Market which returned 12.1% over the past year.
Shareholder returns
| CRAD B | Industry | Market | |
|---|---|---|---|
| 7 Day | 1.5% | 5.5% | 2.1% |
| 30 Day | 3.9% | 1.3% | 1.6% |
| 90 Day | -15.0% | 1.6% | 3.7% |
| 1 Year | 24.8%24.8% | 35.4%34.0% | 16.8%12.1% |
| 3 Year | 215.0%215.0% | 54.9%36.6% | 32.2%12.4% |
| 5 Year | 144.6%141.6% | 72.9%44.6% | 62.8%28.3% |
Price Volatility Vs. Market
How volatile is C-Rad's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 days ago | Simply Wall St
How Does Investing In C-Rad AB (publ) (STO:CRAD B) Impact The Volatility Of Your Portfolio?2 weeks ago | Simply Wall St
Can C-Rad AB (publ)'s (STO:CRAD B) ROE Continue To Surpass The Industry Average?1 month ago | Simply Wall St
Why C-Rad AB (publ)’s (STO:CRAD B) Use Of Investor Capital Doesn’t Look GreatValuation
Is C-Rad undervalued compared to its fair value and its price relative to the market?
42.77x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: CRAD B (SEK33.7) is trading above our estimate of fair value (SEK32.81)
Significantly Below Fair Value: CRAD B is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: CRAD B is good value based on its PE Ratio (42.8x) compared to the Medical Equipment industry average (44x).
PE vs Market: CRAD B is poor value based on its PE Ratio (42.8x) compared to the Swedish market (16.9x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate CRAD B's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: CRAD B is overvalued based on its PB Ratio (10.8x) compared to the SE Medical Equipment industry average (4.4x).
Next Steps
Future Growth
How is C-Rad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
24.4%
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as C-Rad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine C-Rad's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- C-Rad competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
Past Performance
How has C-Rad performed over the past 5 years?
31.0%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: CRAD B has become profitable over the past 5 years, growing earnings by 31% per year.
Accelerating Growth: CRAD B has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: CRAD B has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (17.3%).
Return on Equity
High ROE: CRAD B's Return on Equity (25.4%) is considered high.
Return on Assets
ROA vs Industry: CRAD B has a higher Return on Assets than the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: CRAD B's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is C-Rad's financial position?
Financial Position Analysis
Short Term Liabilities: CRAD B's short term assets (SEK108.4M) exceeds its short term liabilities (SEK48.8M)
Long Term Liabilities: CRAD B's short term assets (108.4M) exceeds its long term liabilities (32.7M)
Debt to Equity History and Analysis
Debt Level: CRAD B is debt free.
Reducing Debt: CRAD B has no debt compared to 5 years ago when its debt to equity ratio was 23.3%.
Debt Coverage: CRAD B has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: CRAD B has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: CRAD B has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if CRAD B's debt is covered by short term assets.
Next Steps
Dividend
What is C-Rad's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate CRAD B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate CRAD B's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if CRAD B's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CRAD B's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CRAD B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
Next Steps
Management
What is the CEO of C-Rad's salary, the management and board of directors tenure and is there insider trading?
4.5yrs
Average management tenure
CEO
Tim Thurn (38yo)
6.3yrs
Tenure
kr2,284,000
Compensation
Mr. Tim Thurn has been the Chief Executive Officer and President of C-Rad AB since July 1, 2013. Mr. Thurn has been the Chief Executive Officer of C-Rad Imaging AB since 2014. He served as the President at ...
CEO Compensation Analysis
Compensation vs. Market: Tim's total compensation ($USD237.11K) is about average for companies of similar size in the Swedish market ($USD123.35K).
Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.
Management Age and Tenure
4.5yrs
Average Tenure
38yo
Average Age
Experienced Management: CRAD B's management team is considered experienced (4.5 years average tenure).
Board Age and Tenure
3.3yrs
Average Tenure
57yo
Average Age
Experienced Board: CRAD B's board of directors are considered experienced (3.3 years average tenure).
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 18,221 |
| Max Price | kr37.21 |
Ownership Breakdown
Management Team
Tim Thurn (38yo)
CEO & President
- Tenure: 6.3yrs
- Compensation: kr2.28m
Ling Zhang (48yo)
Global Marketing Manager
- Tenure: 4.5yrs
Therése Björklund (38yo)
Chief Financial Officer
- Tenure: 0.6yrs
Board Members
Lars Nyberg (68yo)
Chairman of the Board
- Tenure: 3.3yrs
- Compensation: kr400.00k
Åsa Hedin (57yo)
Director
- Tenure: 2.8yrs
- Compensation: kr200.00k
Kicki Wallje-Lund (66yo)
Director
- Tenure: 4.8yrs
- Compensation: kr200.00k
Per Hamberg (46yo)
Director
- Tenure: 6.4yrs
- Compensation: kr200.00k
David Sjöström (45yo)
Director
- Tenure: 2.4yrs
- Compensation: kr200.00k
Company Information
C-Rad AB (publ)'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: C-Rad AB (publ)
- Ticker: CRAD B
- Exchange: OM
- Founded: 2004
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr1.045b
- Shares outstanding: 31.02m
- Website: https://www.c-rad.se
Number of Employees
Location
- C-Rad AB (publ)
- Bredgränd 18
- Uppsala
- Uppsala County
- 753 20
- Sweden
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| CRAD B | OM (OMX Nordic Exchange Stockholm) | Yes | Class B Shares | SE | SEK | Jul 2007 |
Biography
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two seg ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/21 21:01 |
| End of Day Share Price | 2019/10/21 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.